Business Context and Reporting Period
Company: uniQure N.V. (Nasdaq: QURE)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2026
Business Overview: uniQure is a gene therapy company focused on rare and devastating diseases. Key clinical programs include AMT-130 (Huntington's disease), AMT-260 (refractory mesial temporal lobe epilepsy), and AMT-191 (Fabry disease). The company discontinued its AMT-162 (ALS) program in September 2025.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $3,562 | $1,567 |
| Net Loss | $(53,535) | $(43,637) |
| Loss Per Share (Basic & Diluted) | $(0.85) | $(0.82) |
| Operating Expenses | $(49,463) | $(47,245) |
| Research & Development (R&D) | $(29,176) | $(36,140) |
| Selling, General & Administrative (SG&A) | $(20,068) | $(10,908) |
| Cash & Cash Equivalents | $139,994 | $80,240 |
| Total Liquidity (Cash + Investments) | $586,550 | $622,541 |
| Long-Term Debt | $49,942 | $49,699 |
| Royalty Financing Liability | $482,334 | $473,199 |
Note: Liquidity includes cash, cash equivalents, and current investment securities. The company reported a net cash increase of $59.7 million for the quarter, driven primarily by investing activities (maturity of debt securities).
Material Changes vs. Prior Period
- Revenue Growth: License revenues increased by $2.0 million (127%) to $3.6 million, driven by royalty payments from CSL Behring related to HEMGENIX sales.
- Expense Volatility:
- R&D Expenses: Decreased by $7.0 million to $29.2 million. This reduction was primarily due to the discontinuation of the AMT-162 program and a $2.6 million favorable change in the fair value of contingent consideration related to the uniQure France acquisition.
- SG&A Expenses: Increased significantly by $9.2 million to $20.1 million. The increase was driven by higher personnel costs (recruitment for potential AMT-130 commercial launch), increased professional fees, and higher share-based compensation.
- Non-Operating Items: The company recognized a $3.8 million gain from the change in fair value of the liability related to pre-funded warrants issued in September 2025. Conversely, foreign currency losses increased to $2.3 million (compared to a $7.2 million gain in Q1 2025).
- Liquidity Position: While cash and cash equivalents increased by $60 million, total investment securities decreased by approximately $96 million due to maturities, resulting in a net decrease in total liquidity of roughly $36 million compared to the prior year-end.
Guidance, Outlook, and Risks
Regulatory and Clinical Outlook
- AMT-130 (Huntington's): The FDA stated in March 2026 that Phase I/II data compared to an external control are insufficient for a Biologics License Application (BLA). The FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. The company plans to submit a UK Marketing Authorization Application in Q3 2026.
- AMT-191 (Fabry): Dosing in mid- and high-dose cohorts was paused in February 2026 following asymptomatic Grade 3 liver enzyme elevations (dose-limiting toxicity) in two patients.
- AMT-260 (Epilepsy): Enrollment continues in the GenTLE Phase I/IIa trial.
Liquidity and Capital Resources
Management believes current cash and investment resources ($588.1 million) are sufficient to fund operations into the second half of 2029. The company has a $50 million senior secured term loan with Hercules Capital, with an interest-only period potentially extendable to 2030 if commercial milestones are met.
Risks and Contingencies
- Legal Proceedings: A class action lawsuit (Christopher Scocco v. uniQure N.V.) was filed in February 2026 alleging false statements regarding the AMT-130 Phase I/II study and BLA timing. The company intends to vigorously defend the action but cannot estimate potential losses.
- Contractual Changes: In April 2026, the company entered into agreements to terminate its obligation to supply HEMGENIX to CSL Behring once specified batches are delivered (expected mid-2026), designating Genezen as CSL Behring's contract manufacturer.
- Regulatory Uncertainty: The requirement for a new Phase III trial for AMT-130 in the U.S. represents a significant capital and timeline risk.
Key Facts for Investor Verification
- FDA Feedback on AMT-130: Verify the specific requirements for the recommended prospective, randomized, double-blind, sham surgery-controlled study and the associated cost and timeline implications.
- AMT-191 Safety Pause: Monitor the resolution of the dose-limiting toxicity (liver enzyme elevations) and the timeline for resuming dosing in the Fabry disease trial.
- Class Action Litigation: Track the status of the Scocco lawsuit filed in February 2026 regarding disclosures on AMT-130.
- UK Regulatory Pathway: Confirm the submission date and regulatory feedback for the UK Marketing Authorization Application for AMT-130 planned for Q3 2026.
- Manufacturing Transition: Verify the completion of the transition of HEMGENIX manufacturing obligations from uniQure to Genezen/CSL Behring as outlined in the April 2026 termination agreements.